Harbin Pharmaceutical Co., Ltd. announced that Harbin Pharmaceutical Group Bioengineering Co., Ltd., a wholly-owned subsidiary of the company, plans to sign a “technology transfer contract” with Shanghai Bozhiyan New Pharmaceutical Research Co., Ltd., to purchase clinical approval for dapostat tablets and carry out subsequent development and marketing cooperation. The total contract is estimated to be 44.8 million yuan. This matter does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for consideration. Due to the long drug development cycle and high risk, there is uncertainty at every stage. Investors are kindly requested to pay attention to investment risks.

Zhitongcaijing · 05/30 11:17
Harbin Pharmaceutical Co., Ltd. announced that Harbin Pharmaceutical Group Bioengineering Co., Ltd., a wholly-owned subsidiary of the company, plans to sign a “technology transfer contract” with Shanghai Bozhiyan New Pharmaceutical Research Co., Ltd., to purchase clinical approval for dapostat tablets and carry out subsequent development and marketing cooperation. The total contract is estimated to be 44.8 million yuan. This matter does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for consideration. Due to the long drug development cycle and high risk, there is uncertainty at every stage. Investors are kindly requested to pay attention to investment risks.